• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical Effects of Dual Antiplatelet Therapy or Aspirin Monotherapy after Acute Minor Ischemic Stroke or Transient Ischemic Attack, a Meta-Analysis
CONCLUSIONS: Among patients with acute minor ischemic stroke or TIA, DAPT, as compared with aspirin monotherapy, might offer better effectiveness in terms of ischemic stroke recurrence at the expense of a higher risk of major bleeding. The trade-off between ischemic benefits and bleeding risks should be assessed in tailoring the therapeutic strategies.PMID:34323179 | DOI:10.2174/1381612827666210728102459
Source: Current Pharmaceutical Design - July 29, 2021 Category: Drugs & Pharmacology Authors: Francesco Condello Gaetano Liccardo Giuseppe Ferrante Source Type: research

Antithrombotic therapy in carotid artery disease.
Abstract The management of asymptomatic atherosclerotic carotid artery disease and the role of antithrombotic therapy of increasing importance for stroke prevention. Noninvasive imaging of carotid plaques can identify high-risk plaque features that are associated with the risk for plaque rupture. Carotid plaque necrosis, hemorrhage, fibrous cap thinning, and the presence of foam cells have all been correlated with the risk of rupture and onset of neurological symptoms in patients with carotid stenosis. Antiplatelets are currently recommended for patients with a history of ischemic stroke and/or significant carotid...
Source: Current Pharmaceutical Design - May 17, 2020 Category: Drugs & Pharmacology Authors: Papanikolaou P, Antonopoulos AS, Mastorakou I, Angelopoulos A, Kostoula E, Mystakidi XV, Simantiris S, Galiatsatos N, Oikonomou E, Tousoulis D Tags: Curr Pharm Des Source Type: research

Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future.
CONCLUSION: Thrombolytic therapy is sometimes accompanied by harmful hemorrhagic insults; accordingly, a window of time wherein therapy can safely be performed has been established for this approach. Several basic and clinical studies are ongoing to develop next-generation thrombolytic drugs to expand the time window. PMID: 30892155 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - March 17, 2019 Category: Drugs & Pharmacology Authors: Shibata K, Hashimoto T, Miyazaki T, Miyazaki A, Nobe K Tags: Curr Pharm Des Source Type: research

Is very low LDL-C harmful?
CONCLUSION: Achieving an LDL-C of 40-50 mg/dl seems to be safe, and importantly might offer CV beneficial effects. Data for attaining levels below 25 mg/dl is limited, however in favor of such reductions. PMID: 30295187 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 8, 2018 Category: Drugs & Pharmacology Authors: Faselis C, Imprialos K, Grassos H, Pittaras A, Kallistratos M, Manolis A Tags: Curr Pharm Des Source Type: research

Anti-epileptic Drug (AED) Use in Subarachnoid Hemorrhage (SAH) and Intracranial Hemorrhage (ICH).
In conclusion, a well-designed randomized, double blinded, and appropriately powered trial is needed to evaluate the incidence as well as clinical outcomes in patients with aSAH and ICH who received AED prophylaxis versus controls. The results will be extremely valuable in providing evidence to establish management guidelines for patients with hemorrhagic stroke. PMID: 29086673 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 30, 2017 Category: Drugs & Pharmacology Authors: Feng R, Mascitelli J, Chartrain AG, Margetis K, Mocco J Tags: Curr Pharm Des Source Type: research

Lenticulostriate artery and Lenticulostriate-artery Neural Complex: New concept for Intracerebral Hemorrhage.
CONCLUSION: LSAs and the circumferential deep brain are an interactive and mutually affected entity. We propose a new concept called lenticulostriate-artery neural complex (LNC) to integrate the structural, functional and pathological characteristics of this area, which would be a pragmatic paradigm in directing the future basic and clinical studies on ICH. PMID: 28228074 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 19, 2017 Category: Drugs & Pharmacology Authors: Hu R, Feng H Tags: Curr Pharm Des Source Type: research

Endothelial Progenitor Cells As A Therapeutic Approach For Intracerebral Hemorrhage.
CONCLUSION: An EPC-based therapy, acting primarily through angiogenic mechanisms, may be a valid therapeutic option in ICH. PMID: 28003010 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 20, 2016 Category: Drugs & Pharmacology Authors: Pías-Peleteiro J, Campos F, Pérez-Mato M, López-Arias E, Rodríguez-Yáñez M, Castillo J, Sobrino T Tags: Curr Pharm Des Source Type: research

Antithrombotic treatment management in patients with intracerebral hemorrhage: reversal and restart.
CONCLUSION: Although no one can deny the usefulness of antithrombotic therapy a therapeutic strategy should be developed in order to optimize the clinical decision of stopping, reversing and restarting antithrombotic treatment. This review concludes in strong recommendations, yet a multidisciplinary panel by a stroke physician or neurologist, a cardiologist, a neuroradiologist and a neurosurgeon should evaluate the benefits and the risks for each patient and decide the best therapeutic strategy. PMID: 27917716 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 4, 2016 Category: Drugs & Pharmacology Authors: Giakoumettis D, Alexiou GA, Vrachatis DA, Themistoklis K, Stathis P, Vavuranakis M, Themistocleous MS Tags: Curr Pharm Des Source Type: research

Dual or single antiplatelet therapy after transcatheter aortic valve implantation? A systematic review and meta-analysis.
CONCLUSION: DAPT compared to SAPT in patients after TAVI increases incidence of hemorrhagic events with no benefits in terms of thrombotic events and cardiovascular mortality. However, these data must be interpreted cautiously and the choice of DAPT over SAPT must be based on an individual patient characteristic according to medical practice criteria. PMID: 27262328 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 31, 2016 Category: Drugs & Pharmacology Authors: Raut JS, Karuppayil SM, Gazouli M, Vavuranakis M, Siasos G, Zografos T, Oikonomou E, Vrachatis D, Kalogeras K, Papaioannou T, Kolokathis MA, Moldovan C, Tousoulis D Tags: Curr Pharm Des Source Type: research

Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes.
Abstract Recent findings indicate cardiovascular disease (CVD) risk is best predicted by asleep systolic blood pressure (SBP), and lowering it by scheduling ≥1 conventional long-acting hypertension medications, alone or in combination, at bedtime significantly lessens vascular-associated risks. Some 20 years ago, four controlled-onset extended-release drug-delivery systems incorporating a calcium channel blocker or β-blocker, with the treatment goal specifically being attenuation of morning rather than asleep BP, were conceived as one type of bedtime hypertension chronotherapy. However, the CONVINCE outcomes tr...
Source: Current Pharmaceutical Design - October 24, 2014 Category: Drugs & Pharmacology Authors: Smolensky MH, Hermida RC, Ayala DE, Portaluppi F Tags: Curr Pharm Des Source Type: research